Drug Oncology

Akeega

Payments companies reported to CMS as associated with Akeega. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$2.5Massociated payments (2023-2025)

7,228clinicians with associated payments

6companies reporting

By year

2023 $45K

2024 $2.0M

2025 $398K

Payments reported as associated with Akeega, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Urology $1.1M

Hematology & Oncology $437K

Medical Oncology $374K

Family $172K

Physician Assistant $94K

Nurse Practitioner $53K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Akeega

These are the largest totals companies reported as associated with Akeega. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Scott Sellinger	Tallahassee, FL	Urology	$144,776.73
Mahdi Taha	Boca Raton, FL	Medical Oncology	$85,955.28
Erin Pierce	New Orleans, LA	Family	$69,282.69
Amit Mehta	Cary, NC	Hematology & Oncology	$66,983.64
Nancy Dawson	Washington, DC	Medical Oncology	$50,090.08
Aaron Berger	Chicago Ridge, IL	Urology	$37,997.04
Vitaly Margulis	Dallas, TX	Urology	$34,368.47
Jose De La Cerda	San Antonio, TX	Urology	$34,105.01
Lawrence Gervasi	Middleburg Heights, OH	Urology	$33,983.86
Jacek Pinski	Los Angeles, CA	Medical Oncology	$32,146.46

Prescribed Akeega?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.